BR0212468A - Compoto de uréia ativos como antagonistas de receptor de vanilóides para o tratamento de dor - Google Patents

Compoto de uréia ativos como antagonistas de receptor de vanilóides para o tratamento de dor

Info

Publication number
BR0212468A
BR0212468A BR0212468-8A BR0212468A BR0212468A BR 0212468 A BR0212468 A BR 0212468A BR 0212468 A BR0212468 A BR 0212468A BR 0212468 A BR0212468 A BR 0212468A
Authority
BR
Brazil
Prior art keywords
compounds
receptor antagonists
vanilloid receptor
pain treatment
urea compound
Prior art date
Application number
BR0212468-8A
Other languages
English (en)
Inventor
Harshad Kantilal Rami
Mervyn Thompson
Paul Adrian Wyman
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0122156A external-priority patent/GB0122156D0/en
Priority claimed from GB0130503A external-priority patent/GB0130503D0/en
Priority claimed from GB0130505A external-priority patent/GB0130505D0/en
Priority claimed from GB0130547A external-priority patent/GB0130547D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR0212468A publication Critical patent/BR0212468A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"COMPOSTOS DE URéIA ATIVOS COMO ANTAGONISTAS DE RECEPTOR DE VANILóIDES PARA O TRATAMENTO DE DOR". Certos compostos de fórmula (I) : ou um sal farmaceuticamente aceitável do mesmo, ou um solvato do mesmo, em que R^ 1^, R~ 2~, P, P<39>,n, p, q, r e s são como definidos no relatório descritivo, um processo para preparar tais compostos, uma composição farmacêutica compreendendo tais compostos e o uso de tais compostos e da composição para o tratamento de distúrbios que se relacionam ao receptor de vanilóides (VR1) , tais como a dor, a enxaqueca, a neuropatia, a isquemia, a neurodegeneração, o acidente vascular cerebral, a esclerose múltipla, a asma, as doenças inflamatórias.
BR0212468-8A 2001-09-13 2002-09-13 Compoto de uréia ativos como antagonistas de receptor de vanilóides para o tratamento de dor BR0212468A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0122156A GB0122156D0 (en) 2001-09-13 2001-09-13 Novel compounds
GB0130503A GB0130503D0 (en) 2001-12-20 2001-12-20 Novel compounds
GB0130505A GB0130505D0 (en) 2001-12-20 2001-12-20 Novel compounds
GB0130547A GB0130547D0 (en) 2001-12-20 2001-12-20 Novel compounds
PCT/GB2002/004206 WO2003022809A2 (en) 2001-09-13 2002-09-13 Urea-compounds active as vanilloid receptor antagonists for the treatment of pain

Publications (1)

Publication Number Publication Date
BR0212468A true BR0212468A (pt) 2004-10-19

Family

ID=27447989

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212468-8A BR0212468A (pt) 2001-09-13 2002-09-13 Compoto de uréia ativos como antagonistas de receptor de vanilóides para o tratamento de dor

Country Status (32)

Country Link
US (1) US8063078B2 (pt)
EP (3) EP2036902A3 (pt)
JP (2) JP4463552B2 (pt)
KR (3) KR100955967B1 (pt)
CN (1) CN1247568C (pt)
AP (1) AP1818A (pt)
AR (1) AR038786A1 (pt)
AT (1) ATE420083T1 (pt)
AU (1) AU2002329397B2 (pt)
BR (1) BR0212468A (pt)
CA (1) CA2458632C (pt)
CY (1) CY1109449T1 (pt)
DE (1) DE60230773D1 (pt)
DK (1) DK1425277T3 (pt)
EA (1) EA007731B1 (pt)
ES (1) ES2316607T3 (pt)
HK (1) HK1066534A1 (pt)
HU (1) HUP0401923A3 (pt)
IL (2) IL160755A0 (pt)
MA (1) MA26216A1 (pt)
MX (1) MXPA04002379A (pt)
MY (1) MY138086A (pt)
NO (3) NO327009B1 (pt)
NZ (1) NZ531137A (pt)
OA (1) OA12659A (pt)
PE (1) PE20030417A1 (pt)
PL (1) PL213639B1 (pt)
PT (1) PT1425277E (pt)
SI (1) SI1425277T1 (pt)
TW (1) TWI283665B (pt)
UY (1) UY27446A1 (pt)
WO (1) WO2003022809A2 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI283665B (en) * 2001-09-13 2007-07-11 Smithkline Beecham Plc Novel urea compound, pharmaceutical composition containing the same and its use
WO2003066595A2 (en) 2002-02-01 2003-08-14 Euro-Celtique S.A. 2 - piperazine - pyridines useful for treating pain
CA2476936A1 (en) * 2002-02-20 2003-08-28 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
US7279493B2 (en) 2002-06-28 2007-10-09 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
GB0221157D0 (en) * 2002-09-12 2002-10-23 Glaxo Group Ltd Novel treatment
WO2004024710A1 (en) * 2002-09-13 2004-03-25 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
WO2004052846A1 (en) 2002-12-06 2004-06-24 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives
GB0229808D0 (en) * 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7528151B2 (en) 2003-03-06 2009-05-05 Glaxo Group Limited Heterocyclic urea derivatives for the treatment of pain
JP2006519806A (ja) * 2003-03-07 2006-08-31 グラクソ　グループ　リミテッド 尿素誘導体および疼痛治療におけるバニロイド受容体拮抗剤としてのそれらの使用。
GB0305426D0 (en) 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
JP5279987B2 (ja) 2003-05-20 2013-09-04 味の素株式会社 アミド誘導体
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
GB0319150D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
GB0319151D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
CA2540647C (en) 2003-10-01 2012-07-10 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
JP4935073B2 (ja) 2003-10-14 2012-05-23 味の素株式会社 エーテル誘導体
CA2542494A1 (en) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
US7683076B2 (en) 2003-11-08 2010-03-23 Bayer Schering Pharma Aktiengesellschaft Tetrahydro-quinolinylurea derivatives
WO2005095327A1 (ja) 2004-03-31 2005-10-13 Ajinomoto Co., Inc. アニリン誘導体
EP1768954A4 (en) 2004-06-24 2008-05-28 Incyte Corp 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS
WO2006007851A2 (en) 2004-07-19 2006-01-26 Novo Nordisk A/S Capsaicin inhibitors for treating obesity and-related disorders
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
WO2006098554A1 (en) * 2005-03-16 2006-09-21 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
EP1889830A1 (en) * 2006-07-10 2008-02-20 Pharmeste S.r.l. Biarylcarboxyarylamides as vanilloid-1 receptor modulators
KR101410318B1 (ko) * 2006-07-27 2014-06-27 (주)아모레퍼시픽 바닐로이드 수용체 길항제로서의 신규 화합물, 그의 이성질체, 또는 약제학적으로 허용가능한 그의 염, 및 이를함유하는 약제학적 조성물
EP1882687A1 (en) * 2006-07-27 2008-01-30 Amorepacific Corporation Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
TW200824687A (en) 2006-08-25 2008-06-16 Abbott Lab Compounds that inhibit TRPV1 and uses thereof
JP2010513557A (ja) 2006-12-20 2010-04-30 アボット・ラボラトリーズ 疼痛治療のためのｔｒｐｖ１バニロイド受容体アンタゴニストとしてのｎ−（５，６，７，８−テトラヒドロナフタレン−１−イル）尿素誘導体および関連化合物
EP2323989A4 (en) 2008-03-20 2011-06-22 Abbott Lab METHODS FOR PREPARING AGENTS FOR THE CENTRAL NERVOUS SYSTEM THAT ARE TRPV1 ANTAGONISTS
CN101983197B (zh) 2008-04-18 2015-04-22 大熊制药株式会社 新型苯并噁嗪苯并咪唑衍生物、含有该衍生物的药物组合物及其用途
JP4746713B2 (ja) 2008-05-07 2011-08-10 大日本住友製薬株式会社 環状アミン−１−カルボン酸エステル誘導体およびそれを含有する医薬組成物
WO2010026128A1 (en) * 2008-09-02 2010-03-11 Glaxo Group Limited N-(3-methyl-5-isoquinolinyl)-n'-((3r)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl) urea for the treatment of rhinitis
JP2012501315A (ja) * 2008-09-02 2012-01-19 グラクソ グループ リミテッド 鼻炎を治療するためのｔｒｐｖｌアンタゴニストｓｂ−７０５４９８
JP2013028536A (ja) * 2009-11-11 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 環状アミン−１−カルボン酸エステル誘導体およびそれを含有する医薬組成物
WO2012045729A1 (en) 2010-10-05 2012-04-12 Glaxo Group Limited Imidazo [1, 2 -a] pyridine and pyrazolo [1, 5 -a] pyridine derivatives as trpv1 antagonists
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
WO2012072512A1 (en) 2010-11-29 2012-06-07 Glaxo Group Limited N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists
GB201101517D0 (en) * 2011-01-28 2011-03-16 Proximagen Ltd Receptor antagonists
US8754101B2 (en) 2011-04-11 2014-06-17 Glaxo Group Limited N-cyclobutyl-imidazopyridine-methylamine as TRPV1 antagonists
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3424761A (en) 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3424760A (en) 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
EP0347000B1 (en) 1988-06-17 1994-10-26 The Procter & Gamble Company The use of vanilloids for the manufacture of a medicament for treating herpes simplex infections
HU206082B (en) 1988-12-23 1992-08-28 Sandoz Ag Process for producing capsaicin derivatives and pharmaceutical compositions comprising such compounds
CA2017383A1 (en) 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
WO1992009285A1 (en) 1990-11-27 1992-06-11 The Procter & Gamble Company Combinations of vanilloid compounds and phosphonate antiviral compounds for treatment of herpes infections
US5149704A (en) * 1991-05-03 1992-09-22 Abbott Laboratories Platelet activating antagonists
CA2197364A1 (en) * 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
WO1999000121A1 (en) * 1997-06-26 1999-01-07 Eli Lilly And Company Antithrombotic agents
WO1999000128A1 (en) * 1997-06-26 1999-01-07 Eli Lilly And Company Antithrombotic agents
JP2000080085A (ja) * 1997-09-01 2000-03-21 Kyorin Pharmaceut Co Ltd ６，７−非対称ジ置換キノキサリンカルボン酸誘導体とその付加塩及びそれらの製造方法
EP1154989B1 (en) 1999-02-22 2005-12-14 Pacific Corporation Vanilloid analogues containing resiniferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof
WO2000055139A2 (en) 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic urea and related compounds useful as anti-inflammatory agents
CA2384240A1 (en) * 1999-10-15 2001-04-26 Dean A. Wacker Benzylcycloalkyl amines as modulators of chemokine receptor activity
MXPA03000458A (es) 2000-07-20 2004-06-02 Neurogen Corp Ligandos receptores de capsaicina.
KR100453080B1 (ko) 2000-08-21 2004-10-15 주식회사 태평양 신규 티오카르밤산 유도체 및 이를 함유하는 약제학적조성물
CN100439332C (zh) 2000-08-21 2008-12-03 株式会社太平洋 硫脲衍生物以及包含该衍生物的药物组合物
ATE328868T1 (de) 2000-08-21 2006-06-15 Pacific Corp Neue (thio)harnstoffverbindungen und arzneimittelkompositionen, die diese enthalten
JP2002080073A (ja) 2000-09-07 2002-03-19 Kyokuto Kobunshi Kk 電子レンジ用自動開孔袋
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
GB0110901D0 (en) 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
TWI283665B (en) * 2001-09-13 2007-07-11 Smithkline Beecham Plc Novel urea compound, pharmaceutical composition containing the same and its use
RU2005102004A (ru) * 2002-06-27 2005-10-20 Шеринг Акциенгезельшафт (De) Замещенные хинолины как антагонисты рецептора ccr5
WO2004024710A1 (en) 2002-09-13 2004-03-25 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
GB0229808D0 (en) 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
EP1740557A1 (en) 2004-04-20 2007-01-10 Bayer HealthCare AG Urea derivatives as antagonists of the vanilloid receptor (vr1)

Also Published As

Publication number Publication date
KR20090026369A (ko) 2009-03-12
NZ531137A (en) 2006-08-31
NO20041003L (no) 2004-06-04
KR20040041610A (ko) 2004-05-17
US8063078B2 (en) 2011-11-22
MXPA04002379A (es) 2004-05-31
DK1425277T3 (da) 2009-03-16
NO20085078L (no) 2004-06-04
PE20030417A1 (es) 2003-08-06
NO327009B1 (no) 2009-04-06
SI1425277T1 (sl) 2009-04-30
PT1425277E (pt) 2009-03-05
US20090163506A1 (en) 2009-06-25
EP1425277B1 (en) 2009-01-07
CA2458632C (en) 2011-08-23
PL369026A1 (en) 2005-04-18
CA2458632A1 (en) 2003-03-20
ATE420083T1 (de) 2009-01-15
EP1425277A2 (en) 2004-06-09
AP2004002982A0 (en) 2004-03-31
EP2298757A3 (en) 2011-12-28
IL160755A (en) 2009-09-01
EP1425277B8 (en) 2009-04-01
PL213639B1 (pl) 2013-04-30
EA200400432A1 (ru) 2004-12-30
EP2298757A2 (en) 2011-03-23
HK1066534A1 (en) 2005-03-24
DE60230773D1 (de) 2009-02-26
MY138086A (en) 2009-04-30
KR100955967B1 (ko) 2010-05-04
WO2003022809A2 (en) 2003-03-20
KR101063679B1 (ko) 2011-09-07
HUP0401923A3 (en) 2012-09-28
AR038786A1 (es) 2005-01-26
TWI283665B (en) 2007-07-11
CN1247568C (zh) 2006-03-29
CY1109449T1 (el) 2014-08-13
NO20085077L (no) 2004-06-04
JP4463552B2 (ja) 2010-05-19
AU2002329397B2 (en) 2006-04-27
EA007731B1 (ru) 2006-12-29
UY27446A1 (es) 2003-04-30
CN1553905A (zh) 2004-12-08
ES2316607T3 (es) 2009-04-16
JP2005504074A (ja) 2005-02-10
WO2003022809A3 (en) 2003-07-17
OA12659A (en) 2006-06-19
MA26216A1 (fr) 2004-07-01
AP1818A (en) 2008-01-07
JP2010100632A (ja) 2010-05-06
HUP0401923A2 (hu) 2005-01-28
EP2036902A2 (en) 2009-03-18
IL160755A0 (en) 2004-08-31
KR20100082390A (ko) 2010-07-16
EP2036902A3 (en) 2009-05-06

Similar Documents

Publication Publication Date Title
BR0212468A (pt) Compoto de uréia ativos como antagonistas de receptor de vanilóides para o tratamento de dor
BRPI0408681A (pt) compostos, composições farmacêuticas, uso de um derivado da 1,2,3,4-tetraidroisoquinolina, método para tratar ou prevenir doenças, processo para a manufatura de composições farmacêuticas, e, uso de um ou mais compostos
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
WO2002072536A8 (en) Urea derivatives having vanilloid receptor (vr1) antagonist activity
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
MY137535A (en) New pyrrolidinium derivatives
BR0200782A (pt) Compostos para o tratamento da isquemia
MXPA04002583A (es) Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1).
SE0100568D0 (sv) Compounds
BR0113176A (pt) Compostos biciclo-pirazol, composições farmacêuticas compreendendo os compostos, uso dos compostos na fabricação de medicamentos, processos para a preparação dos compostos, coleção quìmica combinatória e métodos para o tratamento de mamìferos incluindo humanos utilizando os compostos
MXPA03009439A (es) Derivados de 4,5-dihidro-1h-pirazol que tienen una potente actividad antagonistica de cb1.
BR0312464A (pt) Inibidores de tirosina quinases
WO2003048164A3 (en) Adenosine a2a receptor antagonists
BR0210028A (pt) Agentes antibacterianos
DE602004023946D1 (de) Kombinationen aus einem arylanilin-beta-2-adrenozeptor-agonisten und einem corticosteroid
BR9812492A (pt) Composto, uso do mesmo, formulação farmacêutica, e, processos para o tratamento de uma doença cardiovascular, para o tratamento de uma vasoconstrição, e para a preparação de compostos
UY27593A1 (es) Nuevos compuestos
BR0308133A (pt) Forma polimórfica cristalina de cloridrato de irinotecan
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
DE60215313D1 (de) Indolderivate und deren verwendung als gnrh antagonisten
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
BR0013283A (pt) Agente farmacêutico que compreende um derivado de benzamida como ingrediente ativo
WO2004078744A3 (en) Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
DE60217292D1 (de) Veterinärmedizinische dermatologische zusammensetzung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 207/00, A61P 29/00

Ipc: C07D 207/00 (2011.01)

B15K Others concerning applications: alteration of classification

Free format text: ALTERADA INT.CI. C07D 207/00

Ipc: C07D 401/04 (2006.01), C07D 401/12 (2006.01), C07D

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2323 DE 14-07-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.